Novo Nordisk A/S (NYSE:NVO) is ranked among the top NYSE stocks with high upside potential. UBS recently downgraded the company to Neutral from Buy, lowering the price target to DKK 340 from DKK 600 on August 5. The firm predicts challenging times ahead due to US compounding of weight loss drugs.

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company focused on diabetes care. It develops, manufactures, and markets pharmaceutical products, with operations divided into biopharmaceuticals and diabetes and obesity care segments. The company faces uncertainty regarding its drug Wegovy due to US weight loss drug compounding.

An elderly couple receiving insulin symbolizes Novo Nordisk A/S’ successful pharmaceutical products. Despite potential as an investment, other AI stocks may offer greater upside potential and less downside risk. For those interested in undervalued AI stocks benefiting from Trump-era tariffs and onshoring trend, a free report on the best short-term AI stock is available.

Read more at Yahoo Finance: Novo Nordisk (NVO) Gets Downgraded to Neutral from Buy at UBS